rss
J Med Genet 45:239-243 doi:10.1136/jmg.2007.054437
  • Letters to JMG

A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1α

  1. F R Zahir1,
  2. A Baross2,
  3. A D Delaney3,
  4. P Eydoux4,
  5. N D Fernandes5,
  6. T Pugh3,
  7. M A Marra1,3,
  8. J M Friedman1
  1. 1
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
  2. 2
    Genome British Columbia, Vancouver, Canada
  3. 3
    BC Cancer Agency Genome Sciences Center, Vancouver, Canada
  4. 4
    Department of Pathology and Laboratory Medicine, Children’s and Women’s Health Centre of BC, Vancouver, Canada
  5. 5
    Faculty of Medicine, University of British Columbia, Vancouver, Canada
  1. Ms F Zahir, Medical Genetics Research Unit, University of British Columbia, Box 153, Children’s and Women’s Hospital, 4500 Oak Street, Vancouver, BC, Canada, V6H 3N1; farahz{at}interchange.ubc.ca
  • Received 8 September 2007
  • Revised 14 November 2007
  • Accepted 16 November 2007
  • Published Online First 5 December 2007

Abstract

The authors report a patient with mild mental retardation, autistic features, multiple vertebral malformations, and an unusual facial appearance who carries a de novo submicroscopic deletion of chromosome 2p16.3. The patient’s deletion is ∼320 kb in size and includes only the part of the NRXN1 gene that codes for the neurexin1α promoter and initial coding exons. The more downstream neurexin1β promoter and the region surrounding it are intact. Neurexin1β has been associated with autism in several recent studies, but this is the first reported patient with loss of only neurexin1α and not of neurexin1β. These findings suggest that neurexin1α function in correct dosage is necessary for normal neurological development.

Footnotes

  • Funding: This work was supported by funding from Genome Canada and Genome British Columbia. MA Marra is a scholar of the Michael Smith Foundation for Health Research.

  • Competing interests: None.

  • Ethics approval: These studies were approved by the University of British Columbia Research Ethics Board.

  • Patient consent: Informed consent was obtained for the publication of the patient’s details in this report, and for the publication of fig 1.